Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s close yesterdayGSK CEO Miels says deals expands lung cancer treatmentsDeal size ‌a departure from smaller bolt-on deals for GSKGSK shares slip in early trading, Nuvalent seen soaring LONDON, June 9...

Full Story Read More